Select Page

Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th

Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th
609683.png

The company has recently announced ongoing cannabis extract research and development targeting four specific health issues.

DALLAS, April 09, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online presentation scheduled next week for Wednesday, April 17th, where management will provide details on its patented cannabis extract treatments targeting a $170 million pharmaceutical market opportunity currently under development.

The company has recently announced ongoing cannabis extract research and development targeting four specific health issues: Chronic Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain Management, and Epilepsy.  The market for Type 2 Diabetes is expected to be a $64 billion market by 2026.

The market for COPD treatment is anticipated to reach $14 billion by 2025.  The overall pain management treatment market is anticipated to reach $83 billion by 2024.  The market for epilepsy treatment is anticipated to reach $9 billion by 2022.

Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline which will be highlighted in the April 17th presentation.

Leave a Reply

avatar

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!